mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
NPJ Vaccines. 2021 Apr 16;6(1):57. doi: 10.1038/s41541-021-00311-w.
NPJ Vaccines. 2021.
PMID: 33863911
Free PMC article.